Predict your next investment

HEALTHCARE | Biotechnology
bindtherapeutics.com

See what CB Insights has to offer

Founded Year

2006

Stage

Asset Sale | AssetsPurchased

Total Raised

$127.98M

Revenue

$0000 

About BIND Therapeutics

BIND Therapeutics, formerly BIND Biosciences, is a biopharmaceutical company leveraging its medicinal nanoengineering platform to design, engineer and manufacture targeted therapeutics. Medicinal nanoengineering complements medicinal chemistry to enable predictable, cost-effective, and rapid development of products with efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications, or life cycle extension for mid- and late-stage products. BIND's initial product development efforts were in the areas of oncology, cardiovascular disorders, inflammatory disease, and RNAi therapeutics.

BIND Therapeutics Headquarter Location

325 Vassar Street

Cambridge, Massachusetts, 02139,

United States

617-491-3400

Latest BIND Therapeutics News

Palleon Pharmaceuticals Appoints Denis Patrick to Its Board of Directors

Dec 16, 2021

December 16, 2021 08:00 AM Eastern Standard Time WALTHAM, Mass.--( BUSINESS WIRE )-- Palleon Pharmaceuticals , a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced the appointment of Denis Patrick, Ph.D., to its Board of Directors. Dr. Patrick is Vice President and Head of Partnering Innovation at Pfizer and a Managing Partner at Pfizer Ventures, the venture capital arm of Pfizer Inc. “Denis’ experience at multiple major biopharmaceutical companies and his knowledge of oncologic drug discovery will contribute greatly to Palleon’s mission to develop better therapies for patients,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “We are thrilled to welcome him to our Board and look forward to collaborating with him as we continue to move forward with the company’s drug discovery and development initiatives into 2022 and beyond. Denis will replace Dr. Nikola Trbovic, whom we would like to thank for his many contributions to Palleon during 2021.” Currently, Dr. Patrick serves as a Board member of FoRx Therapeutics, Metabomed, Mission Therapeutics, and EvolveImmune Therapeutics. Prior to joining Pfizer Ventures, Dr. Patrick served as Head of Oncology Licensing for Worldwide R&D at Pfizer, where he executed the acquisitions of Medivation and BIND Therapeutics and secured research licenses with eight biopharmaceutical companies. Prior to his work at Pfizer, Dr. Patrick served as Director of Oncology Scientific Licensing and Business Development at GlaxoSmithKline, where he was responsible for evaluating clinical and pre-clinical oncologic drugs for potential in-licensing. He began his career as a research scientist at Merck in the drug discovery sector for cancer. Dr. Patrick earned his Ph.D. in biochemistry from the University of Pennsylvania. “Palleon is charting new possibilities in immuno-oncology thanks to their scientific leadership in the field of glycobiology, and it’s an exciting time to join those efforts,” said Dr. Patrick. “As a member of the Board, I look forward to collaborating with this exceptional team to improve and extend the lives of patients suffering from serious diseases.” About Palleon Pharmaceuticals Palleon Pharmaceuticals is the leading biotechnology company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases. The company’s proprietary platforms overcome scientific hurdles that limited progress in the glycobiology field to create novel therapeutics for devastating diseases characterized by immune system dysfunction. Palleon’s lead program in oncology, E-602, is an enzymatic degrader of immunosuppressive sialoglycans on tumors and immune cells which is expected to enter clinical testing in refractory cancer patients in early 2022. www.palleonpharma.com . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BIND Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BIND Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

BIND Therapeutics Patents

BIND Therapeutics has filed 45 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/18/2016

9/11/2018

Experimental cancer drugs, Polymers, Amines, Antineoplastic drugs, Monoclonal antibodies

Grant

Application Date

2/18/2016

Grant Date

9/11/2018

Title

Related Topics

Experimental cancer drugs, Polymers, Amines, Antineoplastic drugs, Monoclonal antibodies

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.